Federal Register
Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program- Facts included
- The rule finalizes and codifies the Medicare Drug Price Negotiation Program ("Negotiation Program").
- The rule establishes certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program ("Part D Program").
- These actions are required by the Inflation Reduction Act of 2022.
- The final rule also finalizes a proposed policy for specific fixed combination drugs that are new formulations.
- Sourcing
- High – the information comes directly from the official rule text.
- Framing
- The document is a factual regulatory announcement without opinion; it reports the content of the final rule.